Want to see RMD full AI Analyst Report?
RMD Stock Chart & Stats
$195.27
$7.81(4.00%)
At close: 4:00 PM EDT
$195.27
$7.81(4.00%)
Day’s Range― - ―
52-Week Range$180.27 - $293.81
Previous Close$203.08
Volume1.14M
Average Volume (3M)1.50M
Market Cap
$30.25B
Enterprise Value$31.89K
Total Cash (Recent Filing)$1.66B
Total Debt (Recent Filing)$843.17M
Price to Earnings (P/E)20.3
Beta0.57
Next Earnings
Aug 06, 2026EPS Estimate
2.89Next Dividend Ex-DateN/A
Dividend Yield1.14%
Share Statistics
EPS (TTM)10.38
Shares Outstanding145,056,380
10 Day Avg. Volume1,243,506
30 Day Avg. Volume1,502,914
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)6.34
Price to Sales (P/S)7.36
P/FCF Ratio22.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$242.30Price Target Upside24.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)12.05
Revenue Forecast (FY)$5.94B
Bulls Say, Bears Say
Bulls Say
High & Expanding Gross MarginsSustained ~62% gross margins and recent +290bps expansion reflect durable product gross economics, pricing power, and supply‑chain gains. Management’s multi‑year margin accretion plan through 2030 implies structural operating leverage that supports long‑term profit sustainability.
Strong Cash Generation And Low LeverageHigh operating cash flow relative to income, robust FCF conversion and a net cash position give ResMed durable financial flexibility to fund R&D, M&A, dividends and buybacks without stressing the balance sheet, reducing refinancing and solvency risks over the medium term.
Recurring Consumables & Connected Care Network EffectsAn installed device base driving recurring mask and accessory sales plus connected software data creates sticky revenue streams. Evidence of GLP‑1 patients boosting resupply demonstrates a structural demand tailwind and higher lifetime value for installed users.
Bears Say
RCS (Residential Care Software) UnderperformanceSlow growth in RCS indicates weakness in a targeted software vertical, limiting diversification and margin expansion from enterprise software. If senior‑care adoption lags, management must either reallocate resources or accept lower software growth, weighing on longer‑term recurring revenue potential.
Rising Operating Expenses And Reinvestment DragMaterial increases in SG&A and R&D as a share of revenue create pressure on operating leverage. Sustained higher expense run‑rates for go‑to‑market and integration activities could compress medium‑term margins unless topline growth persistently outpaces reinvestment.
Reimbursement & Channel Economics Risk For Premium MasksVariable reimbursement and potential HME margin compression for premium fabric masks threaten the recurring consumables model. If payers restrict coverage, adoption and resupply rates could fall or shift to cash‑pay, weakening a key durable revenue stream and pressuring long‑term unit economics.
Resmed News
RMD FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was $180.26 and its highest was $293.81 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $30.25B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Apr 30, 2026. The company reported $2.86 earnings per share for the quarter, beating the consensus estimate of $2.795 by $0.065.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 1.14%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.89.
How many shares outstanding does Resmed have?
Resmed has 145,056,380 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.86 in its last earnings report, beating expectations of $2.795. Following the earnings report the stock price went down -4.111%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in RMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$242.30 (24.08% Upside)
$242.30 (24.08% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 86%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 6.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.90%
12-Months-Change
Fundamentals
Return on Equity
1.14%
Trailing 12-Months
Asset Growth
16.09%
Trailing 12-Months
Company Description
Resmed
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
RMD Company Deck
RMD Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: durable revenue growth (11% headline, 8% constant), material gross margin expansion (+290 bps YoY), double‑digit EPS growth (~21%), strong free cash flow and capital returns, successful product rollouts (fabric masks, AirSense 11) and large real‑world evidence supporting a GLP‑1 demand tailwind. Management acknowledged and is actively managing a set of medium‑term headwinds — including rising SG&A and R&D investments, isolated investment write‑downs, RCS vertical challenges, component cost pressures, and near‑term acquisition dilution — but positioned these as manageable given a strong balance sheet, ongoing supply chain productivity initiatives, and targeted M&A.View all RMD earnings summariesRMD Revenue Breakdown
51.79% Devices
35.75% Masks and other
12.46% Software as a Service
RMD Stock 12 Month Forecast
Average Price Target
$242.30
▲(24.08% Upside)
Technical Analysis
Ownership Overview
0.53% Insiders
16.74% Mutual Funds
2.38% Other Institutional Investors
50.87% Public Companies and Individual Investors